Published in Hepatitis Weekly, February 7th, 2000
Approximately 1.2 million people in the USare chronic carriers of hepatitis B. Lamivudine currently is used as a single-agent treatment. However, treatment with nucleoside analogues alone can result in drug-resistant mutations of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.